Close
Close

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Access Programs

Disease Information

Descriptive Information
Brief Title † Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults
Official Title † A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects
Brief Summary Study design: Single-blind (subject and observer-blinded), active-controlled, randomized [6:2:1:2:1; CL184 + purified vero cell rabies vaccine (PVRV) vs. human rabies immune globulin (HRIG) + PVRV vs. placebo + PVRV vs. CL184 + human diploid cell vaccine (HDCV) vs. placebo + HDCV], mono-center study Study objectives: Primary: To evaluate the safety of CL184 in combination with PVRV in healthy adult subjects. Secondary: To evaluate the safety of HRIG or placebo in combination with PVRV and to evaluate the safety of CL184 or placebo in combination with HDCV in healthy adult subjects. To evaluate the rabies virus neutralizing activity (RVNA) after administration of CL184 or placebo in combination with PVRV, of HRIG in combination with PVRV, and of CL184 or placebo in combination with HDCV in healthy adult subjects. To evaluate the pharmacokinetics of the monoclonal antibodies (mAbs).
Detailed Description This study was designed to explore and obtain further safety and RVNA data on CL184 in comparison to HRIG and placebo as part of a classical post-exposure prophylaxis (PEP) regimen. This regimen will be applied as simulated PEP regimen to healthy subjects (i.e. in a pre-exposure setting) in this study. A comparison with placebo combined with each rabies vaccine was included to differentiate between the contribution of immune globulin and vaccine and to investigate potential interactions between immune globulin and vaccine. RVNA provided by CL184 or HRIG, as well as vaccination response will be checked regularly during the study and booster doses can be applied after the study, if necessary. In addition pharmacokinetic data will be collected.
Study Phase Phase 2
Study Type † Interventional
Study Design † Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary Outcome Measure † Number of participants with adverse events as a measure of safety
Secondary Outcome Measure † Rabies virus neutralizing activity
Condition † Rabies
Intervention † BiologicalRabies virus-specific monoclonal antibodies
Study Arms / Comparison Groups CL184+PVRV CL184 with rabies vaccine (PVRV) HRIG+PVRV HRIG with rabies vaccine Placebo+PVRV Placebo with rabies vaccine (PVRV) CL184+HDCV CL184 with rabies vaccine (HDCV) Placebo+HDCV Placebo with rabies vaccine (HDCV)
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Biological
Estimated Enrollment † 240
Start Date † December 2011
Completion Date December 2012
Primary Completion Date October 2012
Eligibility Criteria † Inclusion Criteria: - Male or female subject aged ≥18 to ≤55 years - Subjects free of obvious health-problems or with stable conditions or medications - Body mass index between ≥18 to ≤30 kg/m2 - Abstinence from sexual intercourse or use of adequate contraception from the date of screening up to Day 90 - Male subjects must agree that they will not donate sperm from the first check-in until Day 90 - Subject signed written informed consent Exclusion Criteria: - Prior history of active or passive rabies immunization - Clinically significant acute illness or infection including fever (≥38 °C) within 2 weeks before first dosing - History and/or family history of clinically significant immunodeficiency or auto-immune disease - Planned immunization with live vaccines during the coming 3 months after first dosing - Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of investigational medicinal product
Gender Both
Ages 18 Years - 55 Years
Accepts Healthy Volunteers Accepts Healthy Volunteers
Contacts ††
Location Countries † India
Administrative Information
NCT ID † NCT01228383
Organization ID RAB-M-A008
Secondary IDs †† U1111-1120-1647
Responsible Party Sponsor
Study Sponsor † Crucell Holland BV
Collaborators ††
Investigators † Principal Investigator: G Nagashayana, MD, Lotus Labs Pvt. Ltd, Bangalore, India
Information Provided By
Verification Date April 2013
First Received Date † October 13, 2010
Last Updated Date April 3, 2013
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
by Abidemi Uruejoma
187 views
Free Newsletter